High-Throughput Screening Fluorescence Polarization Assay for Tumor-Specific Hsp90

Abstract

Heat shock protein 90 (Hsp90) is a molecular chaperone that has emerged as an important target in cancer and several other diseases, such as neurodegenerative diseases, nerve injuries, inflammation, and infection. Discovery of novel agents that inhibit Hsp90 and have druglike properties is therefore a major focus in several academic and industrial laboratories. In this study, the authors describe the development and optimization in a 384-well format of a novel assay for the identification of Hsp90 inhibitors using fluorescence polarization, which measures competitive binding of red-shifted fluorescently labeled geldanamycin (GM-cy3B) to Hsp90 found in the NCI-N417 small-cell lung carcinoma cells. The authors demonstrate that GMcy3B binds with high affinity and specificity to cellular Hsp90. The assay results in excellent signal-to-noise ratios (>10) and Z′ values (>0.75) at tracer concentrations greater than 4 nM and 1 µg/well of total NCI-N417 protein, indicating a robust assay. It also equilibrates after 5 h of incubation at room temperature and remains stable for up to 24 h. Furthermore, it is a simple mix-and-read format that is cost-effective and uses only low amounts of fluorophore and cell lysates. A study using more than 15,000 compounds from the National Institutes of Health Molecular Libraries Screening Center Network was performed to validate its performance in a high-throughput screening format. (Journal of Biomolecular Screening 2007:915-924)

Keywords

tumor Hsp90 fluorescence polarization GM-cy3B small-cell lung carcinoma 384-well format

References

Neckers L. : Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:S55-S61.

Chiosis G. : Targeting chaperones in transformed systems—a focus on Hsp90 and cancer . Expert Opin Ther Targets 2006 ;10:37-50.

McDonald E. , Workman P. , Jones K. : Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr Top Med Chem 2006 ;6:1091-1097.

Soti C. , Nagy E. , Giricz Z. , Vigh L. , Csermely P. , Ferdinandy P. : Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005;146: 769-780.

Chiosis G. , Caldas Lopes E , Solit D. : Hsp90 inhibitors—a chronicle from geldanamycin to today's agents . Curr Opin Investig Drugs 2006;6:534-541.

Prodromou C. , Pearl LH : Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003;5:301-323.

Kamal A. , Thao L. , Sensintaffar J. , Zhang L. , Boehm MF , Fritz LC , et al: A high affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-410.

Sharp S. , Workman P. : Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006;95:323-348.

Carreras CW , Schirmer A. , Zhong Z. , Santi DV : Filter binding assay for the geldanamycin-heat shock protein 90 interaction . Anal Biochem 2003; 317:40-46.

10.

Schilb A. , Riou V. , Schoepfer J. , Ottl J. , Müller K. , Chene P. , et al: Development and implementation of a highly miniaturized confocal 2D-FIDA—based high-throughput screening assay to search for active site modulators of the human heat shock protein 90 beta. J Biomol Screen 2004;9:569-577.

11.

Rowlands MG , Newbatt YM , Prodromou C. , Pearl LH , Workman P. , Aherne W. : High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 2004;327:176-183.

12.

Avila C. , Hadden MK , Ma Z. , Kornilayev BA , Ye QZ , Blagg BS : High-throughput screening for Hsp90 ATPase inhibitors. Bioorg Med Chem Lett 2006;16:3005-3008.

13.

Howes R. , Barril X. , Dymock BW , Grant K. , Northfield CJ , Robertson AG , et al: A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem 2006;350:202-213.

14.

Kim J. , Felts S. , He H. , Llauger L. , Huezo H. , Rosen N. , et al: Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J Biomol Screen 2004;9:375-381.

15.

Vilenchik M. , Solit D. , Basso M. , Huezo H. , Lucas B. , Huazhong H. , et al: Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 2004;11:787-797.

16.

Moulick K. , Clement CC , Aguirre J. , Kim J. , Kang Y. , Felts S. , et al: Synthesis of a red-shifted fluorescence polarization probe for Hsp90. Bioorg Med Chem Lett 2006;16:4515-4518.

17.

Llauger L. , Felts S. , Huezo H. , Rosen N. , Chiosis G. : Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorg Med Chem Lett 2003;13:3975-3978.

18.

He H. , Zatorska D. , Kim J. , Aguirre J. , Llauger L. , She Y. , et al: Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem 2006 ;49:381-390.

19.

Zhang J-H. , Chung Tdy , Oldenburg KR : A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.

20.

Lakowitz JR : Fluorescence anisotropy. In Lakowitz JR (ed): Principles of Fluorescence Spectroscopy. 2nd ed. New York: Plenum , 1999:291-319.

21.

Turek-Etienne TC , Small EC , Soh SC , Xin TA , Gaitonde PV , Barrabee EB , et al: Evaluation of fluorescent compound interference in 4 fluorescence polarization assays: 2 kinases, 1 protease, and 1 phosphatase. J Biomol Screen 2003;8:176-184.

22.

GE Healthcare. Retrieved from http://www.gehealthcare.com/

23.

Llauger L. , He H. , Kim J. , Aguirre J. , Rosen N. , Peters U. , et al: 8-Arylsulfanyl and 8-arylsulfoxyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem 2005 ;48:2892-2905.

24.

Rodina A. , Vilenchik M. , Moulick K. , Aguirre A. , Kim J. , Chiang A. , et al: Selective compounds define Hsp90 as a major inhibitor of apoptosis in small cell lung cancer. Nat Chem Biol 2007 . Published July 1, 2007. Epub ahead of print.

25.

Lobel LI , Morseman JP , Zeng X. , Lustbader JW , Chen H. , Allnutt Fct : Development of a fluorescence based high throughput assay for antagonists of the human chorionic gonadotropin receptor extracellular domain: analysis of peptide inhibitors. J Biomol Screen 2001 ;6:151-158.

26.

Kitamura Y. , Kanda Y. , Onodera H. , Soga S. , Kusaka H, inventors : Preparation of cyclic benzoic acid esters as Hsp90 family protein inhibitors and antitumor agents. US patent WO 2004024142.

27.

Kuramochi H. , Niitsuma S. , Kasuga Y. , Ichikawa Y. , Tomura A. , Shimada J. , et al., inventors: Preparation of dihydroxyphenyl acetylene derivatives as HSP90 inhibitors for the treatment of cancer. US patent WO 2006101052.

28.

Gollob JA , Wilhelm S. , Carter C. , Kelley SL : Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006 ;33:392-406.

29.

Hostein I. , Robertson D. , DiStefano F. , Workman P. , Clarke PA : Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-4009.

30.

Mimnaugh EG , Chavany C. , Neckers L. : Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-22801.

31.

Huezo H. , Vilenchik M. , Rosen N. , Chiosis G. : Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. Chem Biol 2003;10:629-634.